<code id='820486F361'></code><style id='820486F361'></style>
    • <acronym id='820486F361'></acronym>
      <center id='820486F361'><center id='820486F361'><tfoot id='820486F361'></tfoot></center><abbr id='820486F361'><dir id='820486F361'><tfoot id='820486F361'></tfoot><noframes id='820486F361'>

    • <optgroup id='820486F361'><strike id='820486F361'><sup id='820486F361'></sup></strike><code id='820486F361'></code></optgroup>
        1. <b id='820486F361'><label id='820486F361'><select id='820486F361'><dt id='820486F361'><span id='820486F361'></span></dt></select></label></b><u id='820486F361'></u>
          <i id='820486F361'><strike id='820486F361'><tt id='820486F361'><pre id='820486F361'></pre></tt></strike></i>

          
          WSS
          Suzanne KreiterGlobe staff

          The state’s celebrated cluster of biotechs has hatched breakthrough medicines for everything from COVID and cystic fibrosis to multiple rare diseases. It has pioneered cutting-edge research in exotic fields like messenger RNA, gene editing, and gene therapies.

          But when it comes to what is arguably the hottest space in drug development today — controlling weight and diabetes for millions of people worldwide — the brainy innovators from Kendall Square have missed out on the booming market, at least so far.

          advertisement

          Instead, the field, which has scientific roots in Massachusetts, is dominated by a pair of global pharma giants: Denmark’s Novo Nordisk, maker of the blockbuster drugs Wegovy and Ozempic, and Indianapolis-based Eli Lilly, which produces the fast-selling Mounjaro.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion